Tamoxifen for breast cancer among hysterectomised women

U. Veronesi, P. Maisonneuve, V. Sacchini, N. Rotmensz, P. Boyle

Research output: Contribution to journalArticlepeer-review


Tamoxifen is a candidate drug for prevention of breast cancer, although findings from trials have not been consistent. In our extended follow-up (median 81.2 months, IQR 66.0-87.2) of the Italian Tamoxifen Trial, this drug did not significantly protect against breast cancer in women at usual or slightly reduced risk of the disease (p=0.215). Use of hormone replacement therapy increased risk of breast cancer, and users of such treatment who were randomly allocated to tamoxifen had a rate of breast cancer that was close to that of never-users. So far, no woman has died from breast cancer in this study. Decisions about introduction of tamoxifen to reduce risk of breast cancer remain important and open questions.

Original languageEnglish
Pages (from-to)1122-1124
Number of pages3
Issue number9312
Publication statusPublished - Mar 30 2002

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Tamoxifen for breast cancer among hysterectomised women'. Together they form a unique fingerprint.

Cite this